文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗后上尿路尿路上皮癌残留患者的肿瘤学结局

Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
PubMed 文献 · Eur Urol Oncol · 2024-01-22

这项国际多中心回顾性研究纳入1985至2022年间因非转移性高级别上尿路尿路上皮癌行根治性肾输尿管切除术的1993例患者(其中112例接受新辅助化疗),按病理肌层浸润和淋巴结受累分为低危和高危组。低危组中新辅助化疗与未化疗者的无复发生存、总生存和癌症特异性生存相似;高危组中新辅助化疗者的无复发生存(HR 3.07,95%CI 2.10-4.48)、总生存(HR 2.06,95%CI 1.33-3.20)和癌症特异性生存(亚分布HR 2.54,95%CI 1.37-4.69)均劣于病理风险匹配的未化疗者。作者认为新辅助化疗后根治性肾输尿管切除术中残留浸润性疾病者构成独特高危人群,亟需确定最佳辅助治疗方案。

要点

  • 低危病理组中新辅助化疗与未化疗者的无复发生存、总生存和癌症特异性生存相似。
  • 高危病理组中新辅助化疗者的无复发生存(HR 3.07,95%CI 2.10-4.48)劣于未化疗者。
  • 高危病理组中新辅助化疗者的总生存(HR 2.06,95%CI 1.33-3.20)和癌症特异性生存(亚分布HR 2.54,95%CI 1.37-4.69)劣于未化疗者。

核心结论

  • 新辅助化疗后根治性肾输尿管切除术中残留浸润性疾病者构成肿瘤学结局独特的高危人群。
  • 作者认为亟需为这些患者确定最佳辅助治疗方案。

研究设计与样本

  • 回顾性识别1985至2022年间在一大型国际多中心队列中因非转移性高级别上尿路尿路上皮癌行根治性肾输尿管切除术的1993例患者,其中112例接受新辅助化疗。
  • 按根治性肾输尿管切除术时的病理肌层浸润和淋巴结受累发现分为低危组和高危组。
  • 采用Kaplan-Meier法计算无复发生存、总生存和癌症特异性生存,并行多变量分析确定与这些结局相关的临床和人口学因素。

主要发现

  • 低危病理组中新辅助化疗组与未化疗组的无复发生存、总生存和癌症特异性生存相似。
  • 高危病理组中新辅助化疗组较病理风险匹配的未化疗组无复发生存更差(HR 3.07,95%CI 2.10-4.48)。
  • 高危病理组中新辅助化疗组较病理风险匹配的未化疗组总生存更差(HR 2.06,95%CI 1.33-3.20)。
  • 高危病理组中新辅助化疗组较病理风险匹配的未化疗组癌症特异性生存更差(亚分布HR 2.54,95%CI 1.37-4.69)。

临床怎么用

  • 作者认为新辅助化疗后根治性肾输尿管切除术中残留浸润性疾病者应优先纳入临床试验和药物开发。

局限性

  • 缺乏集中病理审查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Growing evidence supports the use of neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC). However, the implications of residual UTUC at radical nephroureterectomy (RNU) after NAC are not well characterized. Our objective was to compare oncologic outcomes for pathologic risk-matched patients who underwent RNU for UTUC who either received NAC or were chemotherapy-naïve. METHODS: We retrospectively identified 1993 patients (including 112 NAC recipients) who underwent RNU for nonmetastatic, high-grade UTUC between 1985 and 2022 in a large, international, multicenter cohort. We divided the cohort into low-risk and high-risk groups defined according to pathologic findings of muscle invasion and lymph node involvement at RNU. Recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) estimates were calculated using the Kaplan-Meier method. Multivariable analyses were performed to determine clinical and demographic factors associated with these outcomes. KEY FINDINGS AND LIMITATIONS: Among patients with low-risk pathology at RNU, RFS, OS, and CSS were similar between the NAC and chemotherapy-naïve groups. Among patients with high-risk pathology at RNU, the NAC group had poorer RFS (hazard ratio [HR] 3.07, 95% confidence interval [CI] 2.10-4.48), OS (HR 2.06, 95% CI 1.33-3.20), and CSS (subdistribution HR 2.54, 95% CI 1.37-4.69) in comparison to the pathologic risk-matched, chemotherapy-naïve group. Limitations include the lack of centralized pathologic review. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with residual invasive disease at RNU after NAC represent a uniquely high-risk population with respect to oncologic outcomes. There is a critical need to determine an optimal adjuvant approach for these patients. PATIENT SUMMARY: We studied a large, international group of patients with cancer of the upper urinary tract who underwent surgery either with or without receiving chemotherapy beforehand. We identified a high-risk subgroup of patients with residual aggressive cancer after chemotherapy and surgery who should be prioritized for clinical trials and drug development.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Fletcher SA, Pallauf M, Watts EK, et al. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024. PMID: 38262800. doi:10.1016/j.euo.2024.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。